Evidence map›Paper›PMID 28604541›Full record

ArticleRetina (Philadelphia, Pa.)2018

HIGH-DOSE HIGH-FREQUENCY AFLIBERCEPT FOR RECALCITRANT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.

Qi Sheng You, Raouf Gaber, Amit Meshi, Hema L Ramkumar, Mostafa Alam, Ilkay Kilic Muftuoglu, William R Freeman

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Retina (Philadelphia, Pa.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Durability of every-8-week aflibercept maintenance therapy in treatment-experienced neovascular age-related macular degeneration.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2019
    Article
  19. Reply.Retina (Philadelphia, Pa.) · 2017
    Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Qi Sheng YouJacobs Retina Center, Shiley Eye Institute, University of California San Diego, La Jolla, California.
Raouf GaberJacobs Retina Center, Shiley Eye Institute, University of California San Diego, La Jolla, California.
Amit MeshiJacobs Retina Center, Shiley Eye Institute, University of California San Diego, La Jolla, California.
Hema L RamkumarJacobs Retina Center, Shiley Eye Institute, University of California San Diego, La Jolla, California.
Mostafa AlamJacobs Retina Center, Shiley Eye Institute, University of California San Diego, La Jolla, California.
Ilkay Kilic MuftuogluJacobs Retina Center, Shiley Eye Institute, University of California San Diego, La Jolla, California.
William R FreemanJacobs Retina Center, Shiley Eye Institute, University of California San Diego, La Jolla, California.
University of California, San Diego · USBeijing Tongren Hospital · CNTanta University · EG

Funding

Vision BiostatisticsP30EY022589 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Derek Stuart Welsbie · 2012 to 2026
$10.3M
NEI NIH HHS P30 EY022589
6 · The paper itself

Abstract

purposeTo determine the efficacy of monthly (0.1 mL/4 mg) aflibercept for refractory neovascular age-related macular degeneration (wet age-related macular degeneration).

methodsThis was a retrospective interventional case series in which patients with wet age-related macular degeneration were treated with stepwise dose escalation. Nonvitrectomized patients resistant to monthly (Q4W) ranibizumab/bevacizumab were switched to 2 mg aflibercept every 8 weeks. With resistance, they were escalated to Q4W 2 mg aflibercept, then Q4W 4 mg (high dose high frequency, 4Q4W) aflibercept. Resistance was defined as ≥2 recurrences after being dry following ≥3 injections or persistent exudation on treatment of ≥5 injections.

resultsThirty-three eyes of 28 patients were treated with 4Q4W aflibercept and followed for a mean of 16 months. A dry retina (no intraretinal or subretinal fluid) was achieved after initiating 4Q4W aflibercept treatment at a mean of 3.8 months. Central foveal thickness, maximum foveal thickness, intraretinal fluid, subretinal fluid, and retinal pigment detachment height decreased significantly at 1 month after initiating the 4Q4W aflibercept, and the morphologic therapeutic effect was sustained until the last visit. Forty-five percent of eyes had one or more lines of vision improvement. New geographic atrophy developed in 9% of eyes during follow-up. No ocular or systemic adverse events occurred after initiating 4Q4W aflibercept.

conclusionIntravitreal high-dose high-frequency aflibercept is an effective treatment for patients with refractory wet age-related macular degeneration.

Indexed as

AgedAged, 80 and overAngiogenesis InhibitorsDose-Response Relationship, DrugDrug Administration ScheduleDrug SubstitutionFemaleHumansIntravitreal InjectionsMaleReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsRetrospective StudiesVisual AcuityWet Macular DegenerationafliberceptAngiogenesis InhibitorsReceptors, Vascular Endothelial Growth FactorRecombinant Fusion Proteins

Identifiers

PMID28604541
PMCPMC5726954
OpenAlexW2622276884

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.